Join us in exploring a new era in cellular therapy

At Rubius Therapeutics®, our vision is to bring potentially life‑changing cellular therapies to people living with cancer. We call these potential medicines Red Cell Therapeutics™.

Learn About
Red Cell Therapeutics™
Find
a Clinical Trial

Open Clinical Studies

Solid Tumors

Rubius Therapeutics is enrolling adults with relapsed/refractory or locally advanced solid tumor cancers into a Phase 1/2 clinical trial to evaluate an investigational potential treatment option, called RTX-240. Refractory refers to patients who have received treatment, but the disease does not go into remission. Some patients experience remission and then a return of the disease, which is referred to as relapsed.

LEARN MORE ABOUT THE RTX-240 CLINICAL TRIAL


Acute Myeloid Leukemia

Rubius Therapeutics is enrolling adults with relapsed acute myeloid leukemia (AML) or refractory AML into a Phase 1/2 clinical trial to evaluate an investigational potential treatment option, called RTX-240. Some patients experience remission and then a return of the disease, which is referred to as relapsed. Refractory AML occurs when patients have received approximately two rounds of chemotherapy, but the disease does not go into remission.

LEARN MORE ABOUT THE RTX-240 CLINICAL TRIAL


HPV 16-Associated Cancers

Rubius Therapeutics is enrolling adults with human papilloma virus (HPV) 16-associated cancers, including cervical cancer, anal cancer and head and neck cancer (including nasal cavity cancer, oral cancer, laryngeal cancer, hypopharyngeal cancer, nasopharyngeal cancer, and oropharyngeal cancer) in a Phase 1 clinical trial to evaluate an investigational potential treatment option, called RTX-321. You may be eligible to participate even if you do not know if your cancer is associated with HPV 16.

LEARN MORE ABOUT THE RTX-321 CLINICAL TRIAL


Thank you

We will contact you about your submission